Tag: Jorge E. Cortes

Rigel Pharmaceuticals gets Rezlidhia FDA approval for AML

Rigel Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Rezlidhia (olutasidenib) capsules for relapsed or refractory (R/R) acute myeloid ... Read More